Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,137,234
  • Shares Outstanding, K 52,872
  • Annual Sales, $ 21,800 K
  • Annual Income, $ -119,330 K
  • 60-Month Beta 1.91
  • Price/Sales 199.42
  • Price/Cash Flow N/A
  • Price/Book 4.71
Trade ARVN with:

Options Overview Details

View History
  • Implied Volatility 72.12%
  • Historical Volatility 45.26%
  • IV Percentile 37%
  • IV Rank 10.72%
  • IV High 170.67% on 12/09/20
  • IV Low 60.29% on 06/24/21
  • Put/Call Vol Ratio 3.00
  • Today's Volume 4
  • Volume Avg (30-Day) 465
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 119
  • Open Int (30-Day) 952

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.72
  • Number of Estimates 9
  • High Estimate -0.37
  • Low Estimate -1.01
  • Prior Year -0.99
  • Growth Rate Est. (year over year) +27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.01 +3.04%
on 11/26/21
97.33 -19.53%
on 11/05/21
-6.93 (-8.13%)
since 10/26/21
3-Month
76.01 +3.04%
on 11/26/21
98.67 -20.62%
on 09/10/21
-5.13 (-6.15%)
since 08/26/21
52-Week
23.42 +234.42%
on 11/30/20
108.46 -27.79%
on 07/29/21
+54.89 (+234.27%)
since 11/25/20

Most Recent Stories

More News
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium

NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated...

ARVN : 78.32 (+0.09%)
PFE : 54.00 (+6.11%)
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference

NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

ARVN : 78.32 (+0.09%)
Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -132.98% and -96.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ARVN : 78.32 (+0.09%)
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

ARVN : 78.32 (+0.09%)
Arvinas to Participate in Upcoming Virtual Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 78.32 (+0.09%)
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported...

ARVN : 78.32 (+0.09%)
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics –

ARVN : 78.32 (+0.09%)
PFE : 54.00 (+6.11%)
Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined...

ARVN : 78.32 (+0.09%)
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference

NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 78.32 (+0.09%)
Arvinas to Present at the UBS Global Healthcare Virtual Conference

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 78.32 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 82.71
2nd Resistance Point 80.91
1st Resistance Point 79.61
Last Price 78.32
1st Support Level 76.52
2nd Support Level 74.72
3rd Support Level 73.42

See More

52-Week High 108.46
Last Price 78.32
Fibonacci 61.8% 75.98
Fibonacci 50% 65.94
Fibonacci 38.2% 55.91
52-Week Low 23.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar